最新
Post-doctoral Fellow – novel PCR technology (Ref.: H01/2026/115)
最新
科技/创新
全职
香港
1 小时前发布
1 小时前发布
工作种类
- 研发
专业
- 生物化学
- 生物工程
- 生物学
- 生物医学工程
工作经验
- 0-3年
职位详情
工作描述
Applications are invited for appointment as Post-doctoral Fellow – novel PCR technology (Ref.: H01/2026/115) for an innovative research project to develop IVD reagents based on a novel system at the Hong Kong Science Park.
职责
- As the leader of a reagent development project, drive the R&D activities with defined goals and timeline, identify and resolve experimental issues based on professional knowledge and literature research.
- As the leader of a reagent development team for this project, mentor the progress of the team.
- Collaborate with the bioinformatics team to interpret experimental results and validate experimental design.
- Work closely with other teams, including instrumentation, production, quality, and marketing to achieve product translation.
- Complete other tasks as required by the team.
入职条件
- Ph.D. degree in biology, chemistry, biomedical engineering, bioengineering, immunology, clinical, or a related field
- Solid background in molecular biology and experimental skills
- R&D experience in industry is preferred
- Experience in droplet microfluidics, digital PCR, next-gen sequencing, or qPCR reagent development is preferred
- Excellent communication and coordination skills
- Strong teamwork abilities
附加信息
Applicants should submit their up-to-date C.V., quoting the job reference number (Ref.: H01/2026/115), with information on current/expected remuneration and availability, to (sigrid.chen@abic.hk). Review of applications will commence as soon as possible and until the posts are filled.
关于公司
概述
The mission of the Advanced Biomedical Instrumentation Centre is to accelerate progress in translating advanced biomedical instrumentation from research and development into real-world healthcare solutions that benefit people in Hong Kong and around the world. The Centre aims to foster collaboration among top-notch engineers, scientists and clinicians in the US and Hong Kong to develop next-generation microfluidics and low-cost instrumentation technologies. It also takes advantage of Hong Kong’ s vibrant start-up community to commercialise the research work tailored for Asian patients.